Angiotech appoints Hank McKinnell to its Board of Directors
13 Mai 2008 - 6:00PM
PR Newswire (US)
VANCOUVER, May 13 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced the appointment of Dr. Hank McKinnell to its Board of
Directors. Dr. McKinnell is the former Chief Executive Officer and
former Chairman of the Board of Directors of Pfizer Inc. He is
currently Chairman of the Accordia Global Health Foundation, an
organization dedicated to fighting infectious diseases in Africa,
and the Lead Director of the Board of Directors of Moody's
Corporation. "We are honoured that Dr. McKinnell has agreed to join
our Board of Directors," said Dr. William Hunter, President and CEO
of Angiotech. "With his history and experience in many roles at
Pfizer, including as Chairman and CEO, Dr. McKinnell brings the
deep industry knowledge and extraordinary leadership qualities that
we will need to facilitate our continued evolution into a
significant, multinational, operating business in the life sciences
sector." Dr. McKinnell joined Pfizer in 1971 in Tokyo and over the
years, held positions of increasing responsibility around the
world, including service as President of Pfizer Asia. In 1984, Dr.
McKinnell relocated to New York, where he served as Vice
President-Strategic Planning, Chief Financial Officer,
President-Pfizer Medical Device Group, President-Pfizer
Pharmaceuticals Group, and President and Chief Operating Officer.
He was named Chairman and Chief Executive officer in 2001 and
served in this role until his retirement in the second half of
2006. Dr. McKinnell is the Chairman Emeritus of the Business
Roundtable, an association of the CEOs of America's largest
companies, the Pharmaceutical Research Manufacturers Association,
the Food and Drug Law Institute, and the Medical Device
Manufacturers Association. He has also served as vice chairman of
the World Economic Forum, as a member of the WEF Foundation Board
of Trustees, and on the President's Advisory Council on HIV/AIDS.
Dr. McKinnell holds a Bachelor's Degree in business from the
University of British Columbia, and M.B.A. and Ph.D. degrees from
the Stanford University Graduate School of Business. About
Angiotech Angiotech Pharmaceuticals, Inc. is a global specialty
pharmaceutical and medical device company with over 1,500 dedicated
employees. Angiotech discovers, develops and markets innovative
treatment solutions for diseases or complications associated with
medical device implants, surgical interventions and acute injury.
To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. CONTACT: Deirdre Neary, Manager,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 222-7056, DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Deirdre Neary, Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 222-7056,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Angiotech Pharmaceuticals - Common Shares (MM) News-Artikel